Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Macular degeneration Diabetic retinopathy Vitreoretinal surgery
Education & Training

Clinical Fellowship , Bascom Palmer Eye Inst & Hosp
Residency , Bascom Palmer Eye Inst & Hosp
Internship , Harvard University
MD , Harvard University

Relationship Between Visual Acuity and Retinal Thickness During Anti–Vascular Endothelial Growth Factor Therapy for Retinal Diseases
Ou, WC, Brown, DM, Payne, JF & Wykoff, CC 2017, American Journal of Ophthalmology, vol 180, pp. 8-17. DOI: 10.1016/j.ajo.2017.05.014

Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study
Wykoff, CC, Ou, WC, Brown, DM, Croft, DE, Wang, R, Payne, JF, Clark, WL, Abdelfattah, NS, Sadda, SVR & TREX-AMD Study Group 2017, Kidney International Reports, vol 2, no. 4, pp. 314-321. DOI: 10.1016/j.oret.2016.12.004

Wykoff, CC, Le, RT, Khurana, RN, Brown, DM, Ou, WC, Wang, R, Clark, WL & Boyer, DS 2017, American Journal of Ophthalmology, vol 177, pp. 236-237. DOI: 10.1016/j.ajo.2017.02.024

Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy
Wykoff, CC 2017, Current Opinion in Ophthalmology, vol 28, no. 3, pp. 213-218. DOI: 10.1097/ICU.0000000000000364

Diabetic retinopathy: A position statement by the American Diabetes Association
Solomon, SD, Chew, E, Duh, EJ, Sobrin, L, Sun, JK, VanderBeek, BL, Wykoff, CC & Gardner, TW 2017, Diabetes Care, vol 40, no. 3, pp. 412-418. DOI: 10.2337/dc16-2641

Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials
Wykoff, CC, Marcus, DM, Midena, E, Korobelnik, JF, Saroj, N, Gibson, A, Vitti, R, Berliner, AJ, Liu, ZW, Zeitz, O, Metzig, C, Schmelter, T & Heier, JS 2017, JAMA ophthalmology, vol 135, no. 2, pp. 107-114. DOI: 10.1001/jamaophthalmol.2016.4912

Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial
Wykoff, CC, Ou, WC, Wang, R, Brown, DM, Cone, C, Zamora, D, Le, RT, Sagong, M, Wang, K & Sadda, SVR 2017, Ophthalmology. DOI: 10.1016/j.ophtha.2017.01.049

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study
Wykoff, CC, Le, RT, Khurana, RN, Brown, DM, Ou, WC, Wang, R, Clark, WL & Boyer, DS 2017, American Journal of Ophthalmology, vol 173, pp. 56-63. DOI: 10.1016/j.ajo.2016.09.029

Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study
Fan, W, Wang, K, Ghasemi Falavarjani, K, Sagong, M, Uji, A, Ip, M, Wykoff, CC, Brown, DM, van Hemert, J & Sadda, SVR 2017, American Journal of Ophthalmology. DOI: 10.1016/j.ajo.2017.05.024

Khurana, RN, Wykoff, CC, Bansal, AS, Akiyama, K, Palmer, JD, Chen, E, Chang, LK, Major, JC, Wu, C, Wang, R, Croft, DE & Wong, TP 2016, Retina. DOI: 10.1097/IAE.0000000000001307

Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad
Croft, DE, Wykoff, CC, Michels, S, Chakravarthy, U & Cruess, AF 2016, American Journal of Ophthalmology, vol 169, pp. xiv-xvi. DOI: 10.1016/j.ajo.2016.06.040

DRCR Protocol-T: Reconciling 1- and 2-year data for managing diabetic macular edema
Wykoff, CC & Hariprasad, SM 2016, Ophthalmic surgery, lasers & imaging retina, vol 47, no. 4, pp. 308-312. DOI: 10.3928/23258160-20160324-01

Diagnostic and Therapeutic Challenges
Corvi, F, Lattanzio, R, Miserocchi, E, Querques, L, Bandello, F, Querques, G, Croft, DE & Wykoff, CC 2016, Retina. DOI: 10.1097/IAE.0000000000000987

Choroidal Neovascularization Secondary to Alexandrite Laser Exposure
Wang, R, Wykoff, CC, Christie, L, Croft, DE, Major, JC, Fish, RH & Brown, DM 2016, Retinal Cases and Brief Reports, vol 10, no. 3, pp. 244-248. DOI: 10.1097/ICB.0000000000000241

Granular hyperreflective specks by spectral domain optical coherence tomography as signs of west nile virus infection: The stardust sign
Wang, R, Wykoff, CC & Brown, DM 2016, Retinal Cases and Brief Reports, vol 10, no. 4, pp. 349-353. DOI: 10.1097/ICB.0000000000000259

ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics
Li, AL, Wykoff, CC, Wang, R, Chen, E, Benz, MS, Fish, RH, Wong, TP, Major, JC, Brown, DM, Schefler, AC, Kim, RY & OMalley, RE 2015, Retina. DOI: 10.1097/IAE.0000000000000901

Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials
Wykoff, C, Elman, MJ, Regillo, C, Ding, B, Lu, N & Stoilov, I 2015, Ophthalmology. DOI: 10.1016/j.ophtha.2016.04.004

Not all retina is created equal: Metabolic quantification of ultra-widefield images
Croft, DE, Wykoff, CC, Van Hemert, J, Verhoek, M & Brown, DM 2015, Ophthalmology, vol 122, no. 12, pp. 2580-2582. DOI: 10.1016/j.ophtha.2015.05.043

Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results
Wykoff, CC, Croft, DE, Brown, DM, Wang, R, Payne, JF, Clark, L, Abdelfattah, NS & Sadda, SR 2015, Ophthalmology, vol 122, no. 12, pp. 2514-2522. DOI: 10.1016/j.ophtha.2015.08.009

Primary rhegmatogenous retinal detachment repair: Evidence supports an individualised approach
Wykoff, CC, Schwartz, SG, Adelman, RA, Brucker, AJ & Flynn, HW 2015, British Journal of Ophthalmology, vol 99, no. 11, pp. 1451-1453. DOI: 10.1136/bjophthalmol-2015-307651